None listed
Conditions
Interventions
None listed
Sponsors
Yonsei University Health System, Gangnam Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pancreatic cancer 1). Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT) 2). Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound 3). Patients who underwent surgical treatment with pancreatic cancer 2. Patients with other carcinomas (biliary cancer, stomach cancer, liver cancer, colon cancer, lung cancer) 1) Biliary cancer: Patients suspected of biliary tract cancer by imaging tests (CT, MRI, PET-CT) and biliary endoscopic examination and confirmed biliary tract cancer by tissue or cytology examination 2) Stomach cancer: Patients suspected of stomach cancer by imaging tests (CT, MRI, PET-CT) and endoscopic examination and confirmed stomach cancer by tissue or cytology examination 3) Liver cancer: Patients suspected of liver cancer by imaging tests (CT, MRI, PET-CT) and confirmed liver cancer by tissue or cytology examination 4) Colorectal cancer: Patients with colorectal cancer suspected by imaging tests (CT, MRI, PET-CT), and colonoscopy and confirmed colorectal cancer by tissue or cytology examination 5) Lung cancer: Patients whose lung cancer is suspected by imaging tests by imaging tests (X-ray, CT, MRI, PET-CT), sputum cell test, and bronchoscope and confirmed lung cancer by tissue or cytology examination 3. Patients with high risk for pancreatic cancer Patient diagnosed with ? chronic pancreatitis ? pancreatic cyst ? benign pancreatic mass ? pancreatic duct dilatation by imaging studies (US, CT, MRI) ? Patients diagnosed with diabetes within two years of age 55 and older ? Patients with elevated CA 19-9 levels (50U / mL or higher; normal reference value: 0.8-24 U / mL) 4. Patients with benign pancreatic disease Patient diagnosed with acute pancreatitis 5. healthy control Those who have not been diagnosed with malignant or pancreatic diseases through a medical examination within 6 months of the decision to participate in the study
Exclusion criteria
Exclusion criteria: 1. Minors under the age of 19, vulnerable subjects such as illiteracy 2. Those who have received immunosuppressive drugs from past medical history
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparative evaluation of cytokine expression in serum of pancreatic cancer patients, other carcinomas (biliary cancer, gastric cancer, liver cancer, colon cancer, lung cancer), patients with high risk of pancreatic cancer, patients with benign pancreatic disease and normal subjects | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of cytokine expression as a factor predicting pancreatic cancer diagnosis and prognosis | — |
Countries
Korea, Republic of
Contacts
Public ContactSung Ill Jang
Yonsei University Health System, Gangnam Severance Hospital
Outcome results
None listed